Endometrial CD8+ T cells predict reproductive outcomes in recurrent implantation failure patients.
This retrospective cohort study analyzed data from 110 patients diagnosed with recurrent implantation failure (RIF). The investigation focused on endometrial immune dysregulation, specifically the proportion of CD8+ T cells, alongside the number of previous implantation failures and embryo quality. The primary outcome measured was reproductive success versus failure.
The analysis identified the number of previous implantation failures as the strongest negative predictor of success, with an adjusted odds ratio (aOR) of 0.74 (95% CI 0.60–0.91; P = 0.004). Conversely, endometrial CD8+ T cell proportion demonstrated a positive, threshold-dependent effect. Above a proportion of 2.0%, each 1% increase in CD8+ T cells raised the odds of success by 25% (aOR = 1.25; 95% CI 1.03–1.52; P = 0.025). Embryo quality also served as an independent positive predictor (aOR = 1.62; 95% CI 1.04–2.53; P = 0.033).
A machine-learning model using XGBoost achieved an area under the curve (AUC) of 0.762 (95% CI 0.734–0.790). Mediation analysis revealed that 22.8% of the total effect was mediated through CD8+ T cells. Furthermore, the protective effect of CD8+ T cells was significantly enhanced in patients with severe immune disorders (interaction P = 0.034). No adverse events or discontinuations were reported in this observational analysis.
Key limitations include the poorly defined specific role of endometrial immune dysregulation and its interactions with clinical factors. The lack of integrated, multimodal predictive models combining clinical history with immune profiling limits the ability to personalize management. While the internally validated model offers a prognostic tool and the CD8+ T cell pathway suggests a potential target for immunomodulation, the study design prevents definitive causal conclusions. These results advance precision management concepts but require prospective validation.